Onco Wiki / Biomarqueur

PSA (contexte de dépistage et de surveillance du cancer de la prostate — grade C de l'USPSTF)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDBIO-PSA-PROSTATE-SCREENING
TypeBiomarqueur
Alias
Contrôle de l'APSAntigène spécifique à la prostate pour le dépistagePSA sériqueПСА (скринінг/нагляд раку передміхурової залози — USPSTF C)
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesDIS-PROSTATE
SourcesSRC-NCCN-PROSTATE-2025 SRC-USPSTF-PROSTATE-2018

Données biomarqueurs

Type de biomarqueurserum_marker
Mesure
MéthodeSerum immunoassay (ECLIA, CLIA); WHO 96/670 calibration preferred
Unitésng/mL
Échelle type
  • 0
  • 4
Biomarqueurs connexesBIO-PSA

Notes

Screening-context entry for PSA — separate from BIO-PSA (which covers diagnostic and treatment-monitoring dynamics for established prostate cancer). USPSTF 2018: Grade C for men 55-69 (individualized shared-decision-making about benefits + harms); Grade D for men ≥70 (recommend AGAINST routine screening). NCCN 2025 (Early Detection): baseline PSA + DRE discussion at age 45 for African American men or BRCA2 carriers (high-risk groups), age 50 for average risk; if PSA <1 ng/mL, repeat every 2-4 years; if PSA 1-3 ng/mL, repeat every 1-2 years; if PSA >3 ng/mL, evaluate further (repeat PSA, mpMRI, biomarker reflex such as 4Kscore/PHI, possible biopsy). Higher screening intensity for confirmed BRCA2 germline carriers (IMPACT study — PSA q1y starting age 40; biopsy threshold ≥3 ng/mL). PSA can be falsely elevated in BPH, prostatitis, urinary retention, recent instrumentation. Free PSA ratio, PSA density, and reflex biomarkers (PHI, 4Kscore, SelectMDx) reduce unnecessary biopsy. Limitations: overdiagnosis/overtreatment of indolent cancers (well-characterized harm — driver of USPSTF Grade C). STUB pending two-Co-Lead signoff.

Utilisé par

Pertinence thérapeutique